Testing a Digital PrEP Toolkit to Help Cisgender Women in Alabama and Mississippi Learn About and Start HIV Prevention Medication

What this Trial Is About

This research aims to evaluate an Interactive Digital PrEP Toolkit designed to help cisgender women in Alabama and Mississippi learn about and access pre-exposure prophylaxis PrEP, a medication that prevents HIV infection. The study focuses on addressing barriers such as limited PrEP awareness, low HIV risk perception, and challenges in client-provider communication, especially in rural southeastern U.S. regions where PrEP use among women remains low. Participants will use the Digital PrEP Toolkit on a tablet during a clinic visit, which includes educational content tailored to women and information about various PrEP options, such as daily pills and injections. After using the Toolkit, participants receive a Personalized HIV Prevention Summary and discuss PrEP options with healthcare staff. Those interested can schedule a PrEP clinic appointment. Follow-up includes phone interviews at 3 months and medical record reviews at 3 and 6 months to assess PrEP uptake and persistence. Participants will be involved in a 30-minute enrollment visit including consent and baseline assessments, use of the Digital PrEP Toolkit, and follow-up interviews. Researchers will evaluate feasibility by measuring Toolkit completion rates and time, acceptability through satisfaction surveys, and preliminary efficacy by tracking PrEP initiation and knowledge changes. Medical records will be reviewed up to 6 months post-enrollment to monitor ongoing PrEP use, with total study participation lasting up to 18 months.

Evaluating an Interactive Digital Toolkit for Women's PrEP Implementation